Pronto disponible para inscripción
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

MTS2: Myopia (near-sightedness) in Young Children - Clinical Trial

¿Cuál es el Propósito de este estudio?

This study is being done to find out if atropine eyedrops (0.05% atropine, 99.95% inactive solution) and/or special eyeglass lenses are an effective strategy to slow down the progression of myopia for young children with nearsightedness.

¿Cuál es la Condición que se está estudiando?

Myopia (Nearsightedness) in Children

¿Quién puede participar en el Estudio?

Children ages 5-11 who:

  • Have myopia
  • Need to wear eye glasses regularly
  • Do not have an allergy to atropine

For more information, contact the study team at corren.white@duke.edu.

¿Qué Implica?

If you choose to have your child join this study, they will participate for about two and a half years. You and your child will come in for a study visit every three months. Half of the visits will be eye exams. The other half will be eyedrop pickup visits where your child won't see the eye doctor.

Your child will also have five visits to get fitted with new study glasses. The study will involve testing how well children can see, how well their eyes focus, and how nearsighted their eyes are. We will also ask your child to answer questions about how well they can see in their everyday activities.

Detalles del Estudio

Título Completo
A Randomized Placebo-Controlled Trial of Spectacles with Highly Aspherical Lenslet Target (H.A.L.T.) MAX Technology or 0.05% Atropine to Slow Progression of Myopia in Children - MTS2
Investigador Principal
Nathan Cheung, OD
Especialista en optometría pediátrica
Número de Protocolo
IRB: PRO00118558
Fase
Phase III
Estado de inscripción
Pronto disponible para inscripción
Apoye la investigación de Duke Health o rinda homenaje a un ser querido con un regalo conmemorativo.
Contribuya a Duke Health